NASA's Artemis II Mission: First Crewed Lunar Journey Since Apollo 
European Stocks Slip as Earnings, UK Inflation and ECB Decision Keep Investors on Edge 
Wistron Opens $700M Texas AI Factory to Build Nvidia Superchips in U.S. 
US-Iran Conflict Escalates as Gulf Attacks Threaten Global Oil Supply 
CDC Monitors U.S. Travelers After Hantavirus Outbreak on Luxury Cruise Ship 
Saudi Oil Tankers Reverse Course as Houthi Threats Disrupt Red Sea Shipping 
Neuralink Expands Brain Implant Trials with 12 Global Patients 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
US Dollar Holds Near One-Week High as Middle East Tensions and Oil Prices Drive Market Sentiment 
Asian Currencies Hold Steady as Middle East Tensions Boost US Dollar, Oil Concerns 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Alphabet Q2 Earnings Beat Estimates as AI Spending, Google Cloud Growth Fuel Outlook 
Trump Set to Unveil New Tariffs on Dozens of Countries as Global 10% Duty Nears Expiration 
Belimo H1 Sales Surge as AI Data Center Cooling Drives More Than Half of Growth 
IBM Q2 Earnings Miss Estimates as Software Growth Offsets Infrastructure Weakness 
US Stock Futures Rise as AI Optimism Lifts Tech, 3M Jumps on Strong Earnings 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
